Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck
Woman and Man
Between 12 years
and 99 years
Merck Sharp & Dohme (MSD)
Update Il y a 4 ans
Étude MK-3475-716 : étude de phase 3 randomisée comparant l’efficacité du pembrolizumab par rapport à un placebo en traitement adjuvant chez des patients ayant un mélanome de stade 2 à haut risque réséqué.
Le mélanome est une tumeur maligne qui prend naissance dans les cellules de la peau, les mélanocytes. Un changement de la couleur, de la taille ou de la forme d’un grain de beauté est souvent le premi...
Country
France
organs
Mélanomes cutanés
Specialty
Immunothérapie - Vaccinothérapie
,
Pédiatrie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
Comparison of Pediatric Formulation (liquid) to Adult Formulation (tablets)
To evaluate the comparative bioavailability between: • MK-5348 (vorapaxar) 0.2085 mg/mL oral suspension from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., USA; and • MK-5348 (Zontiv...
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Merck Serono International SA
Update Il y a 4 ans
Estudio en fase IIIb, multicéntrico, comparado con grupo de control, doble ciego, aleatorizado y de dos brazos, con evaluaciones mensuales por resonancia magnética y biomarcadores para evaluar la eficacia, la seguridad y la tolerabilidad de Rebif New Formulation (IFN beta-1a) en pacientes con esclerosis múltiple remitente-recurrente. A two-arm, randomized, double-blind, control group-compared, multicenter, phase IIIb study with monthly MRI and biomarker assessments to evaluate the efficacy, safety, and tolerability of Rebif® New Formulation (IFN-beta-1a) in subjects with relapsing remitting multiple sclerosis
To evaluate the efficacy of Rebif® New Formulation (RNF), compared to placebo, in subjects with Relapsing Remitting Multiple Sclerosis and active disease by means of Magnetic Resonance Imaging (MRI) a...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
Vaginal ring dysmenorrhea feasibility trial
To identify at least one dose of progestin/estrogen amongst the 4 active doses being tested, administered as a vaginal ring, that shows clinically relevant treatment efficacy in relief of primary dysm...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
Fosaprepitant PK/PD CINV in Pediatric Cancer Patients
To determine the appropriate dosing regimen of fosaprepitant for the prevention of CINV in pediatric patients birth to 17 years of age, by assessing the pharmacokinetic and pharmacodynamic parameters,...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
Update Il y a 4 ans
A clinical study in patients with complicated intra-abdominal infections (infections situated within the cavity of the abdomen) conducted to assess safety, tolerability and efficacy of the study drug (MK-7655) administered together with Imipenem/Cilastatin (an antibiotic) in comparison with Imipenem/Cilastatin administered alone
1. To evaluate the efficacy of two doses of MK-7655 + imipenem/cilastatin (250 mg and 125 mg), as compared with imipenem/cilastatin alone, with respect to the clinical response assessment profile in t...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Generics UK Ltd
Update Il y a 4 ans
A CUMULATIVE DOSE RESPONSE STUDY TO EVALUATE THE THERAPEUTIC EQUIVALENCE OF A NEW SALMETEROL INHALATION AEROSOL CONTAINING A REPLACEMENT HFA PROPELLANT IN A PRESSURISED METERED DOSE INHALER AND EXISTING SALMETEROL–CFC PRODUCT
The primary aim of the study is: To assess the therapeutic equivalence of a new salmeterol HFA-134a formulation compared to a reference salmeterol CFC formulation given in a cumulative dose design.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Merck Sharp & Dohme (MSD)
Update Il y a 4 ans
Étude LEAP-011 : étude de phase 3, randomisée, en double aveugle, comparant l'efficacité et la sécurité du pembrolizumab associé au lenvatinib, par rapport à celles du pembrolizumab associé à un placebo, comme traitement de première ligne, chez des patients ayant un carcinome urothélial localement avancé ou métastatique, avec une tumeur exprimant le PD-L1 pour les patients inéligibles au cisplatine, et quelle que soit l'expression tumorale de PD-L1 chez les patients inéligibles aux chimiothérapies à base de platine (LEAP-011)
Etude de phase III, randomisée, en double aveugle, comparant l'efficacité et la sécurité du pembrolizumab (MK-3475) en combinaison avec le lenvatinib (E7080/MK-7902) versus pembrolizumab plus placebo,...
Country
France
organs
Appareil urinaire - autres
Specialty
Thérapies Ciblées
,
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Merck & Co., Inc
Update Il y a 4 ans
Ensayo de fase III, aleatorizado, controlado con un fármaco de comparación activo, con doble enmascaramiento, de doce semanas de duración, para comparar la eficacia y la seguridad de MK-2452 (0,0015%) sin conservantes y de maleato de timolol (0,5%) sin conservantes en pacientes con glaucoma de ángulo abierto e hipertensión ocular "A Phase III, Randomized, Active Comparator-Controlled, Twelve-Week, Double-Masked Clinical Trial to Compare the Efficacy and Safety of Preservative-Free MK-2452 (0.0015%) and Preservative-Free Timolol Maleate (0.5%) in Patients with Open-Angle Glaucoma and Ocular Hypertension
Evaluar la eficacia de MK-2452 sin conservantes (0,0015 %) en comparación con el maleato de timolol sin conservantes (0,5 %) en lo que se refiere a la variación de la PIO con respecto al valor basal d...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Serono S.A.-Geneva, an affiliate of Merck KGaA Darmstadt, Germany
Update Il y a 4 ans
A randomised, double-blind, placebo-controlled, multicentre prospective dose-finding Phase II/III study with atacicept given subcutaneously to subjects having recently experienced a flare of systemic lupus erythematosus (SLE)
The primary objective of this trial is to evaluate the efficacy of atacicept compared to placebo in preventing new flares in subjects with SLE.
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next